Cachexia is one of oncology’s most feared complications. More than half of patients with advanced non-small cell lung cancer, which accounts for over 85 percent of lung cancer cases, develop the syndrome, which is characterized by anorexia, progressive weight loss and the relentless erosion of skeletal muscle and fat. Unlike simple malnutrition, cachexia cannot be reversed with nutritional support alone. It is driven by systemic inflammation and profound metabolic dysregulation, and it directly contributes to as much as 20 percent of all cancer-related deaths. Patients with cachexia tolerate anti-tumour therapies poorly, suffer diminished quality of life and die sooner. Despite decades of research, no effective pharmacological therapy exists, leaving clinicians to rely on multimodal strategies aimed at reducing inflammation, preserving lean body mass and improving appetite.

The research team, led by Yingjia Zhou, Shaoli Zhao and Huantian Cui, chose Huangqi Guizhi Wuwu Decoction, commonly abbreviated HGWD, because of its well-documented immunomodulatory, anti-inflammatory and microcirculatory properties. The formula is already used clinically in China to manage metabolic dysfunction and immune dysregulation, particularly chemotherapy-related side effects such as peripheral neuropathy. Yet its potential role in tumour-induced cachexia had never been examined. To test it, the researchers implanted Lewis lung carcinoma cells into eight-week-old male C57BL/6 mice, a widely used model of lung cancer cachexia, and randomly assigned fifty animals to five groups: tumour-free controls, untreated cachectic mice, mice treated with the chemotherapy drug cisplatin, and cachectic mice given either a low or high dose of HGWD by daily gastric gavage for fourteen consecutive days.

The results were unambiguous. By days seven and fourteen of treatment, untreated cachectic mice showed a marked decline in grip strength and wire-hang endurance, while mice receiving the high dose of HGWD maintained significantly greater muscle strength. Cisplatin, notably, failed to improve muscle function and in some measures made matters worse. HGWD also increased tumour-free body weight, gastrocnemius and quadriceps muscle mass, and epididymal fat mass, all of which were severely depleted in the untreated cachectic animals. Histological examination confirmed the protective effect: the cross-sectional area of skeletal muscle fibres, which shrank dramatically in cachectic mice, was substantially preserved in the HGWD-treated groups.

At the molecular level, the remedy appeared to reinvigorate the muscle’s own building machinery. Cachectic mice showed sharp reductions in MYHC, MYOD1 and MYOG, proteins essential for myogenesis, along with elevated ATROGIN-1, a key marker of muscle atrophy. HGWD partially restored the myogenic proteins and suppressed ATROGIN-1. The treatment also corrected metabolic and oxidative stress abnormalities in the muscle: glycogen levels, which had collapsed, recovered; lactic acid accumulation diminished; the antioxidant enzymes superoxide dismutase and glutathione peroxidase rebounded; and malondialdehyde, a marker of lipid peroxidation, fell. Intriguingly, HGWD also reduced tumour volume and weight, whereas cisplatin did not rescue, and sometimes worsened, the wasting parameters despite its antitumour action. HGWD-treated mice additionally ate and drank more, a factor the authors acknowledge could contribute to the improvements.

To uncover the mechanism, the team turned to transcriptome sequencing of the gastrocnemius muscle. Comparing untreated cachectic mice with healthy controls revealed widespread disruption of pathways including amino acid biosynthesis, cysteine and methionine metabolism, arginine and proline metabolism, glycolysis, the HIF-1 signalling pathway and cytokine receptor interactions. When the high-dose HGWD group was compared with the untreated cachectic group, the picture shifted dramatically: the most enriched pathways were again dominated by amino acid metabolism, alongside the PPAR signalling pathway, cholesterol metabolism, galactose metabolism and calcium signalling. Crucially, HGWD markedly upregulated genes encoding motor proteins, including Myhas, Mylpf and Myl1, which are critical for maintaining muscle mass, driving myogenesis and regulating contractility.

Untargeted metabolomics of the same muscle tissue told a complementary story. Principal component and discriminant analyses showed that HGWD substantially reshaped the aberrant metabolite profile of cachectic muscle, and pathway enrichment again pointed squarely at amino acid biosynthesis. Among the metabolites restored by the treatment were S-adenosylmethionine, known as SAM, L-arginine, L-tryptophan, L-ornithine, L-leucine and spermidine. Each of these molecules has established links to muscle health: arginine and leucine supplementation has been shown to partially mitigate cachexia in prior studies, accelerated tryptophan catabolism contributes to sarcopenia, ornithine supports mitochondrial and redox function in wasting states, and spermidine plays a well-documented role in protecting against muscle ageing and preserving muscle homeostasis.

The deepest insight came from integrating the two datasets. The researchers found that HGWD upregulated the genes Amd1, Amd2 and Smox while downregulating Gnmt. AMD1 and AMD2 are rate-limiting enzymes that convert SAM into decarboxylated SAM, supplying the propylamine groups needed to synthesize polyamines such as spermidine. SMOX then converts decarboxylated SAM into spermidine, and its expression positively correlates with muscle mass and function. GNMT, by contrast, channels SAM toward S-adenosylhomocysteine, and its dysregulation lowers the SAM/SAH ratio, a change closely linked to muscle ageing and cachexia progression. Western blot analysis confirmed the pattern at the protein level: AMD1 and SMOX rose, GNMT fell. The authors propose that HGWD alleviates cachexia by suppressing GNMT, raising the SAM/SAH ratio and enhancing the conversion of SAM into spermidine, thereby restoring amino acid metabolic homeostasis in skeletal muscle.

The study is not without caveats, which the authors address candidly. Because HGWD also reduced tumour burden and increased food intake, the muscle-protective effect could be secondary to reduced tumour-derived catabolic signalling or improved nutrition rather than a direct metabolic action within muscle tissue; a pair-feeding experiment would be needed to disentangle these possibilities. The findings are also correlational, lacking direct causal proof, and the specific bioactive compounds within the multi-herb formula responsible for the effect remain unidentified. The team plans follow-up work using in vitro myotube atrophy models treated with HGWD-containing serum, combined with siRNA knockdown of AMD1 or SMOX and enzyme inhibitors, alongside multi-omics integration and target-validation techniques such as surface plasmon resonance and drug affinity responsive target stability assays.

Even so, the implications are considerable. With no approved pharmacological therapy for cancer cachexia and more than half of advanced lung cancer patients affected, a well-tolerated, orally available formula that simultaneously preserves muscle, corrects metabolic derangement and modestly inhibits tumour growth represents an unusually attractive therapeutic profile. The identification of the SAM-to-spermidine axis as a plausible mechanism also gives researchers a concrete molecular handle for drug development, whether inspired by the herbal formula itself or by synthetic compounds that mimic its enzymatic effects. For now, the work stands as a rigorous, multi-omics demonstration that a medicine brewed from herbs first described centuries ago can act on modern molecular targets, and it opens a promising path toward clinical evaluation of HGWD in patients whose cancers are stealing their muscle, strength and time.

Subject of Research: Mechanisms of a traditional Chinese medicine formula in treating lung cancer–induced cachexia through amino acid metabolism regulation

Article Title: Huangqi Guizhi Wuwu Decoction Ameliorates Cachexia in Lung Cancer Mice Through Regulating Amino Acid Metabolism: Insights From Transcriptomics, Metabolomics and Experimental Validation

Article References: Zhou, Y., Zhao, S., Shen, H., Wu, J., Li, M., Liu, S., Yang, J., Jin, X., Li, F., & Cui, H. (2026). Huangqi Guizhi Wuwu Decoction Ameliorates Cachexia in Lung Cancer Mice Through Regulating Amino Acid Metabolism: Insights From Transcriptomics, Metabolomics and Experimental Validation. Journal of Cellular and Molecular Medicine, 30(19), Article e71387. https://doi.org/10.1111/jcmm.71387

Image Credits: AI Generated

DOI: 10.1111/jcmm.71387

Keywords: cancer cachexia, lung cancer, Huangqi Guizhi Wuwu Decoction, traditional Chinese medicine, amino acid metabolism, spermidine, S-adenosylmethionine, skeletal muscle atrophy, transcriptomics, metabolomics, Lewis lung carcinoma, myogenesis